Covid-19 roundup: FDA for­mal­ly hands Pfiz­er/BioN­Tech's vac­cine a pri­or­i­ty re­view; Eu­ro­pean reg­u­la­tors look to Kineret to treat at-risk pa­tients

The FDA said last Fri­day that it would give an ex­pe­dit­ed look at the Pfiz­er-BioN­Tech vac­cine for full ap­proval in pa­tients ages 16 and old­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.